R&D News | pharmaphorum

News

AstraZeneca builds in cancer ADCs again, with LaNova deal

AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base

News

AI project aims to strip racial bias from lung disease R&D

A new project has been launched to develop artificial intelligence models that more closely reflect the diversity seen in patients with lung disease in the UK.

News

GSK chases down Pfizer in 5-in-1 meningitis jab contest

Armed with new data, GSK is preparing to file for approval of its new-generation meningitis vaccine, as it tries to maintain its leadership in the category against a chall

News

After FDA snub, DBV charts a new course for Viaskin peanut

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was

News

AI algorithm ‘could improve heart attack diagnosis’

Researchers in the UK have said that an algorithm developed using artificial intelligence could help doctors decide more quickly if a patient has suffered a heart attack,

News

Human ‘pangenome’ could usher in better therapies

It’s been 20 years since the Human Genome Project published its first blueprint of human gene sequences, starting a new era of medical research, but now scientists have go

AstraZeneca builds in cancer ADCs again, with LaNova deal

AI project aims to strip racial bias from lung disease R&D

GSK chases down Pfizer in 5-in-1 meningitis jab contest

After FDA snub, DBV charts a new course for Viaskin peanut

AI algorithm ‘could improve heart attack diagnosis’

Human ‘pangenome’ could usher in better therapies

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks